drug
lefamulin acetate
Marketedupdated 5mo agoby Nabriva Therapeutics US Inc
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Patent cliff
source: FDA Orange Bookfirst barrier falls
Mar 19, 2028
~1.4 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (6)
- Jun 14, 2036formulationUS 12121582
- Mar 25, 2033compositionUS 8071643
- Mar 25, 2033compositionUS 8071643
- May 23, 2031compositionUS 91207274.6y
- Mar 19, 2028compositionUS 81536891.4y
- Mar 19, 2028compositionUS 81536891.4y
FDA exclusivities (4)
- Aug 19, 2029GAINGAIN Antibiotic (5y)2.9y
- Aug 19, 2029GAINGAIN Antibiotic (5y)2.9y
- Aug 19, 2024NCENew Chemical Entity (5y)
- Aug 19, 2024NCENew Chemical Entity (5y)
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 16m ago
Found something off?
comments(0)
5-min edit window · permanent after that